The results of vaccination trials carried out on pups with maternally derived antibodies (MDA) to canine parvovirus (CPV), using a modified-live CPV-2b variant vaccine (29-97/40 strain), are reported. The vaccine was able to overcome the obstacle of MDA, and to elicit protective immunity in 100% of the pups whose antibody titres were 1:10-1:40, 83% of the pups with titres of 1:80, 57% of the pups with titres of 1:160, and even in 60% of the pups with antibody titres of 1:320.
Immunization of pups with maternally-derived antibodies to canine parvovirus (CPV) using a modified - live variant (CPV-2b) / PRATELLI A.; CAVALLI A; NORMANNO G.; DE PALMA M.G.; PASTORELLI G.; MARTELLA V.; BUONAVOGLIA C.. - In: JOURNAL OF VETERINARY MEDICINE. SERIES B. - ISSN 0931-1793. - 47(2000), pp. 273-276.
Immunization of pups with maternally-derived antibodies to canine parvovirus (CPV) using a modified - live variant (CPV-2b)
PRATELLI, Annamaria;CAVALLI, Alessandra;MARTELLA, Vito;BUONAVOGLIA, Canio
2000
Abstract
The results of vaccination trials carried out on pups with maternally derived antibodies (MDA) to canine parvovirus (CPV), using a modified-live CPV-2b variant vaccine (29-97/40 strain), are reported. The vaccine was able to overcome the obstacle of MDA, and to elicit protective immunity in 100% of the pups whose antibody titres were 1:10-1:40, 83% of the pups with titres of 1:80, 57% of the pups with titres of 1:160, and even in 60% of the pups with antibody titres of 1:320.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
